Current Report Filing (8-k)
May 15 2017 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2017
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36783
|
|
20-1450200
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2130 W. Holcombe Blvd., Ste. 800
Houston, TX
|
|
20-1450200
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
832-384-1100
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01 Entry into a Material Definitive Agreement.
Separation and Consulting Agreement
Effective May 10, 2017, Bellicum Pharmaceuticals, Inc. (the Company) entered into a separation and consulting agreement with
Annemarie Moseley, Ph.D., M.D. (the Moseley Agreement). Pursuant to the terms of the Moseley Agreement, Dr. Moseley will resign from her position as the Companys Chief Operating Officer and Executive Vice President of Clinical
Development, effective July 31, 2017 (the Separation Date). Following the Separation Date, Dr. Moseley will receive the following benefits, subject to certain terms and conditions: (i) continued payment of her base salary
for 12 months following the Separation Date, through July 31, 2018 (the Severance Period); (ii) a lump sum amount equal to her
pro-rated
target performance bonus for 2017; and
(iii) payment of COBRA premiums during the Severance Period (subject to earlier termination). In addition, Dr. Moseley agreed to serve as a consultant to the Company commencing on the Separation Date through January 31, 2019 (the
Consulting Period). During the Consulting Period, Dr. Moseley is expected to provide consulting services for up to 10 hours per month, or more if needed, at a rate of $425 per hour. As additional compensation, the Company agreed to
extend the Severance Period for purposes of continued base salary and COBRA payments for an additional six months, through January 31, 2019.
Amended and Restated Employment Agreement
Effective May 10, 2017, the Company entered into an Amended and Restated Employment Agreement (the Smith Agreement) with Alan
J. Smith, Ph.D., in connection with his promotion to Executive Vice President, Technical Operations. Dr. Smith previously was the Companys Senior Vice President of Manufacturing. The Smith Agreement provides that Dr. Smith will
receive an annual base salary of $370,000, less payroll deductions and withholdings, and will be eligible to receive an annual performance bonus with a target amount equal to 40% of his annual base salary. In connection with his promotion,
Dr. Smith was granted an option to purchase 20,000 shares of the Companys Common Stock, which will vest over a four-year period with 25% vesting on the
one-year
anniversary of the grant date and the
remainder vesting monthly thereafter in equal increments for 36 months. Dr. Smith also is entitled to monthly reimbursement of up to $4,000 for reasonable travel costs from Virginia to Texas and reasonable accommodations in Houston.
Dr. Smiths employment with the Company is at will and may be terminated at any time. Under the Smith Agreement Dr. Smith is entitled to severance benefits upon a termination of employment without cause or a
resignation for good reason (each such term as defined in the Smith Agreement), including continued payment of base salary for 12 months, payment of COBRA premiums for 12 months and a
pro-rated
annual performance bonus.
The foregoing descriptions of the Moseley Agreement and the Smith Agreement are not complete and are qualified
in their entirety by reference to the full text of each such agreement, copies of which will be filed as exhibits to the Companys Quarterly Report on Form
10-Q
for the quarter ended June 30, 2017.
On May 15, 2017, the Company issued a press release announcing, among other things, the entry into the Moseley Agreement and the
Smith Agreement. A copy of the press release is attached hereto as Exhibit 99.1.
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The disclosure set forth in Item 1.01
above is incorporated herein for this Item 5.02.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated May 15, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc.
|
|
|
|
|
Date: May 15, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Alan A. Musso
|
|
|
|
|
|
|
Alan A. Musso
|
|
|
|
|
|
|
Chief Financial Officer and Treasurer
|
INDEX TO EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated May 15, 2017.
|
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024